magnifying glass
logo for Eureka Therapeutics

Eureka Therapeutics

Business Services · California, United States · 77 Employees

Get Full Access

Who is Eureka Therapeutics

Eureka Therapeutics, Inc. is a privately-held clinical-stage biotechnology company focused on developing novel T-cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of solid tumors and hematologic malignancies. The company currently has two clinical programs, ET140203 (ARYA1 and ARYA2) and ECT204 (ARYA3), in Phase I/II US trials in patients with advanced liver cancer. Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area.Read More

Headquarters

Headquarters:

5858 Horton St, Ste 362, Emeryville, California, 94608, United States
Phone Number

Phone Number:

(510) 654-7045
Revenue

Revenue:

$40 Million
Eureka Therapeutics's Social Media
SIC Code 87,873
NAICS Code 541,541714
Popular Searches:

EUREKA THERAPEUTICS INC

Eureka Therapeutics

Eureka Therapeutics , Inc.

Eureka Therapeutics, Inc

eurekainc.com

Top Competitors of Eureka Therapeutics

Employess
47
revenue
$50 Million

1

Employess
57
revenue
<$5 Million

2

Employess
69
revenue
$13 Million

3

Employess
<25
revenue
$14 Million

4

Employess
27
revenue
<$5 Million

5

Employess
393
revenue
$132 Million

6

Eureka Therapeutics's Org Chart

PhonePhoneEmailEmail
Hanzhong Li
Hanzhong Li

Senior VP, Corporate Development

PhonePhoneEmailEmail

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Eureka Therapeutics Company Metrics

Company Insights
Employee Growth Rate
Funding
Funding DateRoundAmountInvestors

Mar 17, 2020

Series E

$45M

Lyell Immunopharma

Jan 22, 2018

Series D

$60M

-

Sep 24, 2014

Series C

$21M

Yuan Capital

See More

$133M

Total Funding Amount

$45M

Most Recent Funding Amount

5

Number of Funding Rounds

Revenue
QuarterRevenue

'21 - Q1

40000000

'21 - Q2

40000000

Eureka Therapeutics's Tech Stack

Microsoft PowerPoint

By

Microsoft

Microsoft Project

By

Microsoft

Google Universal Analytics

By

Google
See more technologies

Eureka Therapeutics News & Media

Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a preclinical study in blood entitled “A TCR Mimic CAR T Cell Specific for NDC80 Is Broadly Reactive With Solid Tumors and Hematological Malignancies”. The study was led by Dr. Cheng Liu, President & Chief Executive Officer of Eureka and Dr. Martin Klatt and Dr. David Scheinberg of Memorial Sloan Ke

Eureka Therapeutics to Present at the 18th Annual PEGS Boston Conference and Expo

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Cancer--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, today announced that Dr. Cheng Liu, President and CEO, is scheduled to participate in person at the PEGS Boston Conference and Expo at Hynes Convention Center on May 2-6, 2022. Dr. Liu will be participating in two engagements. He will be hosting a roundtable discussion on the challenges and opportunities of targeting intracellul

Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatocellular Carcinoma (HCC) With ARTEMIS® T Cells

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ET140203 and ECT204 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. Eureka is currently recruiting patients in three Phase I/II clinical trials to investigate the safety and potential ef
Subscribe to "Eureka Therapeutics" News

Frequently Asked Questions regarding Eureka Therapeutics

Where are Eureka Therapeutics’s headquarters?

Eureka Therapeutics’s headquarters are in 5858 Horton St, Ste 362, Emeryville, California, 94608, United States

What is Eureka Therapeutics’s phone number?

Eureka Therapeutics’s phone number is (510) 654-7045

What is Eureka Therapeutics’s official website?

Eureka Therapeutics’s official website is www.eurekatherapeutics.com

What is Eureka Therapeutics’s Revenue?

Eureka Therapeutics’s revenue is $40 Million

What is Eureka Therapeutics’s SIC code?

Eureka Therapeutics’s SIC: 87,873

What is Eureka Therapeutics’s NAICS code?

Eureka Therapeutics’s NAICS: 541,541714

How many employees are working in Eureka Therapeutics?

Eureka Therapeutics has 77 employees

What is Eureka Therapeutics’s industry?

Eureka Therapeutics is in the industry of: Business Services, Research & Development

Who are Eureka Therapeutics’s main competitors?

Eureka Therapeutics's main competitors are: Tmunity Therapeutics, TScan Therapeutics, Tessa Therapeutics, Checkmate Pharmaceuticals

What is Eureka Therapeutics's tech stack?

The technologies that are used by Eureka Therapeutics are: Microsoft PowerPoint, Microsoft Project, Python, Google Universal Analytics

See more information about Eureka Therapeutics
4.4/5 on G2 Crowd